Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

January 15, 2024

Conditions
Colorectal NeoplasmIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmRectal DiseasesColonic DiseasesIntestinal DiseaseGastrointestinal DiseaseDigestive System Disease
Interventions
DIETARY_SUPPLEMENT

Ocoxin-Viusid

"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."

Trial Locations (1)

10400

National Institute of Oncology and Radiobiology (INOR), Havana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma | Biotech Hunter | Biotech Hunter